Get the Stockscreener App
17.45
0.40%
-0.07
Grail Inc stock is traded at $17.45, with a volume of 756.90K.
It is down -0.40% in the last 24 hours and up +34.23% over the past month.
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages.
See More
Previous Close:
$17.52
Open:
$17.45
24h Volume:
756.90K
Relative Volume:
1.02
Market Cap:
$587.34M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+15.64%
1M Performance:
+34.23%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$17.28
$18.37
1-Week Range:
$15.10
$18.37
52-Week Range:
$12.33
$21.47
Grail Inc Stock (GRAL) Company Profile
Name
Grail Inc
Sector
Industry
Phone
650-771-9796
Address
1525 O'BRIEN DRIVE, MENLO PARK
Compare GRAL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRAL
Grail Inc
|
17.45 | 587.34M | 0 | 0 | 0 | 0.00 |
|
TMO
Thermo Fisher Scientific Inc
|
521.66 | 199.82B | 42.37B | 6.14B | 7.78B | 15.26 |
|
DHR
Danaher Corp
|
238.83 | 173.66B | 23.74B | 3.89B | 4.98B | 7.93 |
|
A
Agilent Technologies Inc
|
138.14 | 38.64B | 6.51B | 1.29B | 1.37B | 3.82 |
|
IQV
Iqvia Holdings Inc
|
201.43 | 36.52B | 15.32B | 1.41B | 1.96B | 5.95 |
|
IDXX
Idexx Laboratories Inc
|
421.76 | 34.55B | 3.84B | 866.24M | 792.60M | 9.80 |
Grail Inc Stock (GRAL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Oct-17-24 | Initiated | Guggenheim | Neutral |
Grail Inc Stock (GRAL) Latest News
Grail initiated at equal weight by Morgan Stanley (NASDAQ:GRAL) - Seeking Alpha
Grail (NASDAQ:GRAL) Coverage Initiated by Analysts at Morgan Stanley - MarketBeat
Golden Grail Beverages Cancels Convertible Debt to Reduce Dilution - Yahoo Finance
Grail's CFO Aaron Freidin sells $426,937 in common stock By Investing.com - Investing.com South Africa
Grail's CFO Aaron Freidin sells $426,937 in common stock - Investing.com
GRAIL to Participate in Upcoming Investor Conferences - WV News
Golden Grail Beverages CEO Shares Global Vision in New Interview with SmallCapVoice.com - Yahoo Finance
GRAIL to Present at Piper Sandler and Evercore ISI Healthcare Conferences in December | GRAL Stock News - StockTitan
GRAIL uses lung cancer blood test to determine who needs post-surgery therapy most - Mugglehead
Grail tests first patient for TROPION-Lung12 Phase 3 study - TipRanks
GRAIL Launches FDA-Approved Phase 3 Trial for Breakthrough Lung Cancer Blood Test | AZN Stock News - StockTitan
(GRAL) Trading Report - Stock Traders Daily
Wolfe Research Begins Coverage on Grail (NASDAQ:GRAL) - MarketBeat
Wolfe starts Grail at Peer Perform on time and money needs - TipRanks
Grail initiated with a Peer Perform at Wolfe Research - Nasdaq
Golden Grail Beverages Corp. (OTC: GOGY) Retains SmallCapVoice.com Inc. - The Manila Times
Golden Grail Beverages Slashes Share Count 90%, Plans Strategic Acquisitions for 2025 | GOGY Stock News - StockTitan
GRAIL Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
PRIMECAP Management's Strategic Acquisition of GRAIL Inc Shares - GuruFocus.com
Grail Inc. Reports Strong Galleri Test Growth in Q3 2024 - Nasdaq
GRAIL, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
GRAIL Inc Reports Q3 2024 Revenue of $28.7 Million with Signific - GuruFocus.com
GRAIL Reports Third Quarter 2024 Financial Results - PR Newswire
Quantune joins quest for the holy grail of non-invasive glucose monitoring - TechCrunch
How to Take Advantage of moves in (GRAL) - Stock Traders Daily
Grail (GRAL) Scheduled to Post Earnings on Tuesday - MarketBeat
GRAIL to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum - PR Newswire
Jim Cramer says Reddit’s surge is about ‘raw user power,’ calls it ‘holy grail’ for advertisers - CNBC
GRAIL to Announce Third Quarter 2024 Financial Results - StockTitan
(GRAL) Trading Advice - Stock Traders Daily
Google: The Bullish Pivot Before The Earnings Grail (NASDAQ:GOOG) - Seeking Alpha
GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation - The Cancer Letter
Nike x Wu-Tang Clan Reunite to Release Legendary Sneaker Grail — NIKE, Inc. - Nike
Illumina Wins Court Fight With EU Over $7 Billion Grail Deal - MSN
Real-world study of Grail’s Galleri consistent with trial data - BioWorld Online
The Jeff Bezos-backed cancer treatment company is being sold for eight billion dollars - Telegrafi
GRAIL Presents Initial Results From REFLECTION Real-World Evidence Study of Galleri® Multi-Cancer Early Detection (MCED) Test at the Early Detection of Cancer Conference - PR Newswire
Health Beat: The 'holy grail' of cancer screening - 69News WFMZ-TV
CEO & Director Of GRAIL Sold 51% Of Their Shares - Simply Wall St
Company commits not to try to crack ‘holy grail’ cement-free formula - Irish Independent
Grail appoints healthcare veteran Sarah Krevans to board By Investing.com - Investing.com Australia
Grail appoints healthcare veteran Sarah Krevans to board - Investing.com
GRAIL Appoints Sarah Krevans to Board of Directors - Quantisnow
Layoff Tracker: Takeda Cuts More Employees, Total Exceeds 1,300 in 2024 - BioSpace
Grail CEO Robert Ragusa sells $1.73 million in stock - Investing.com
How the (GRAL) price action is used to our Advantage - Stock Traders Daily
Health Headlines: Holy Grail of cancer screening - KPLC
GRAIL, Inc. (GRAL): Jeff Bezos Is Buying This Stock Now - Insider Monkey
Grail Inc. executive acquires over $1 million in company stock - Investing.com India
Grail Inc. executive acquires over $1 million in company stock By Investing.com - Investing.com South Africa
Grail Inc Stock (GRAL) Financials Data
There is no financial data for Grail Inc (GRAL). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.43%
0.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):